Treatment for NAFLD and NASH
Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
1. A method for treating a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in a subject having metabolic syndrome, comprising administering a therapeutically effective amount of seladelpar or a salt thereof to the subject.
2. A method for treating a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in a subject having metabolic syndrome, comprising orally administering a therapeutically effective amount of seladelpar or a salt thereof to the subject.
3. The method of claim 2 where the daily dose of the seladelpar or a salt thereof administered to the subject is 20-200 mg, when the dose is calculated as seladelpar.
4. The method of claim 3 where the daily dose of the seladelpar or a salt thereof administered to the subject is 50-100 mg, when the dose is calculated as seladelpar.
5. The method of claim 2 where the seladelpar or a salt thereof is administered to the subject once/day.
6. The method of claim 2 where the disease is NAFLD.
7. The method of claim 2 where the disease is NASH.
8. The method of claim 2 where the metabolic syndrome is manifested by insulin resistance.
9. The method of claim 2 where the metabolic syndrome is manifested by type 2 diabetes mellitus.
10. The method of claim 2 where the metabolic syndrome is manifested by abdominal obesity.
11. A method for treating a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in a subject having metabolic syndrome, comprising orally administering a therapeutically effective amount of seladelpar L-lysine dihydrate salt to the subject.
12. The method of claim 11 where the daily dose of the seladelpar L-lysine dihydrate salt administered to the subject is 20-200 mg, when the dose is calculated as seladelpar.
13. The method of claim 12 where the daily dose of the seladelpar L-lysine dihydrate salt administered to the subject is 50-100 mg, when the dose is calculated as seladelpar.
14. The method of claim 11 where the seladelpar L-lysine dihydrate salt is administered to the subject once/day.
15. The method of claim 11 where the disease is NAFLD.
16. The method of claim 11 where the disease is NASH.
17. The method of claim 11 where the metabolic syndrome is manifested by insulin resistance.
18. The method of claim 11 where the metabolic syndrome is manifested by type 2 diabetes mellitus.
19. The method of claim 11 where the metabolic syndrome is manifested by abdominal obesity.